Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab DDI Study in Atopic Dermatitis
NCT02647086Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2015
- Primary completion
- Jul 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dupilumab in atopic dermatitis (AD), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Ratio of Area Under Curve last (AUClast) for Cytochrome P450 substrates at Day 36 and Ratio of Maximum Concentration (Cmax) for Cytochrome P450 substrates at Day 36. Started Dec 2015; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02647086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02647086.